Demand for GLP-1-based weight-loss drugs is rising in Brazil, but high prices and prescription barriers are leaving many people unable to access treatment legally. Multiple outlets report that this gap is helping fuel a clandestine market selling smuggled or counterfeit versions of the medicines.

Bloomberg and Business of Fashion link the growth of the black market to both affordability and eligibility issues, noting that many interested consumers cannot pay the going rates or do not meet requirements for prescriptions. The reporting also highlights broader concerns that illegal supply chains can increase the risk of harm, including potential unsafe products and exposure to criminal networks. While the outlets focus on different aspects—one emphasizing the market’s expansion and public-safety implications, the other underscoring consumer interest versus access limitations—they converge on the central point that the surge in GLP-1 demand is outpacing legitimate availability.

The coverage does not indicate whether enforcement actions are underway or provide verified counts of seizures or participants in the illicit trade, but it frames the situation as an emerging public health concern tied to the medicines’ popularity.